Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Alliance Pharma PLC on Friday said it expects to report 2024 profit broadly in line with the year before, despite a decline in annual revenue.
The Chippenham, Wiltshire-based distributor of consumer healthcare brands and prescription medicines said it expects to report revenue of £180.3 million for 2024, down 1.3% from £182.7 million a year prior.
Revenue within its Kelo-Cote franchise grew 3.4% at constant exchange rates to £65.4 million from £63.2 million, in line with its mid-single digit revenue growth forecast.
The group is targeting a transition to smaller, more regular orders in China, though it notes that this is taking ‘longer than we anticipated’.
Nizoral revenue sank 28% during the year to £16.4 million from £21.7 million, due to the timing of distributor orders, while Amberen revenue fell 10% to £10.1 million from £11.2 million.
Total see-through Consumer Healthcare revenue declined 4.3% at CER to £130.7 million from £136.4 million.
On the other hand, Prescription revenue grew 6.9% to £49.6 million, Forceval revenue rose 18% to £7.9 million, and Hydromol revenue was up 13% on-year to £10.3 million.
Alliance Pharma still anticipates underlying group profit for the year in line with the £31.5 million reported for 2023.
Chief Executive Officer Nick Sedgwick said: ‘I am pleased that performance in 2024 is in-line with expectations. Whilst we have much to do as we work on our transformation plans, I am confident that our strong portfolio of clinically differentiated brands will deliver predictable organic revenue growth over the mid-long term.’
Shares in Alliance Pharma were flat at 61.20 pence each in London on late Friday morning.
Copyright 2025 Alliance News Ltd. All Rights Reserved.